According to Tonix Pharmaceuticals, the United States Patent and Trademark Office has issued the company US Patent 11,389,473,”Magnesium-Containing Oxytocin Formulations and Methods of Use,” which includes claims related to the use of such formulations for the treatment of pain such as migraine headache. The anticipated expiration date for the patent is January 7, 2036.
The company acquired TNX-1900 intranasal potentiated oxytocin for the treatment of migraine from Trigemina in June 2020. In November 2021, Tonix announced that the FDA had cleared its IND for a Phase 2 study of TNX-1900 in migraine patients, and that study is still expected to start by the end of this year, the company says now. Earlier this year, Tonix said that it also planned to initiate a Phase 2 trial of TNX-1900 for the treatment of binge eating disorder in 2022.
Tonix CEO Seth Lederman commented, “The USPTO’s issuance of this patent is an important milestone in protecting our expanding central nervous system therapeutic portfolio. An estimated four million individuals in the United States suffer from chronic migraine. We believe that by engaging and stimulating oxytocin receptors in the trigeminal ganglia, TNX-1900 has the potential to help those chronic migraine sufferers. TNX-1900 contains magnesium, which Tonix has shown potentiates the action of oxytocin at oxytocin receptors in animal models.”
Read the Tonix Pharmaceuticals press release.
